RxDoctor Payments Data

Frederick Dantagnan, MD

Internal Medicine · Metairie, LANPI 1124091574

Payments from drug & device makers

What this record shows

5 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. Reporting peaked in 2022 at $121 and has fallen 64.4% since, to $43 in 2025. That places this record below the midpoint for internal medicine clinicians in LA, where the typical reported total is $379.

$251in general payments, 2019–2025

Across 9 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$98
  • Novo Nordisk$65
  • AbbVie$40
  • Inspire Medical Systems, Inc.$26
  • Pfizer$22
$420,440in research payments, 2019–2025

Across 5 payments — averaging $84,088 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$420K

What the payments were for

  • Food & beverage$12650%
  • Education$12550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$251 in reported general payments places this provider in the 40th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,014
Medicare patients
230
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$111,130
MounjaroTirzepatide60$81,379
JardianceEmpagliflozin66$66,734
EliquisApixaban58$52,222
XareltoRivaroxaban34$28,063
JanuviaSitagliptin Phosphate34$24,605
TrulicityDulaglutide20$23,570
FarxigaDapagliflozin Propanediol20$18,672
TradjentaLinagliptin12$9,155
PremarinEstrogens, Conjugated15$7,460
Repatha SureclickEvolocumab13$6,855
LinzessLinaclotide12$6,375
Breo ElliptaFluticasone/Vilanterol15$5,956
DexilantDexlansoprazole12$5,406
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$111,13088 claims
PfizerEliquis, Premarin, Dilantin$22$61,38485 claims
AstraZenecaFarxiga$98$18,67220 claims
AbbVieLinzess, Synthroid$40$9,80665 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →